2024-11-05 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Analysis**

Eli Lilly and Co. (LLY) is a pharmaceutical company specializing in developing and manufacturing drugs for diabetes, cancer, autoimmune diseases, and other chronic illnesses. 

**Performance Summary:**

* **LLY Cumulative Return:** 761.31%
* **S&P 500 (VOO) Cumulative Return:** 131.28%
* **Performance Gap:** 630.03 (Max: 807.92, Min: -24.98)
* **Relative Performance:** 78.64% (This means LLY's performance has been in the 78.64th percentile relative to the S&P 500 over the period analyzed)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|------|
| 2015 | 20.3% | 13.8% | 21.1% | 1.0 |
| 2016 | -11.2% | 19.2% | -22.6% | 0.8 |
| 2017 | 13.2% | 10.1% | -5.4% | 0.5 |
| 2018 | 36.7% | 14.7% | 43.6% | 0.8 |
| 2019 | 14.4% | 17.2% | -14.2% | 0.7 |
| 2020 | 27.7% | 22.1% | 12.5% | 0.7 |
| 2021 | 66.9% | 18.6% | 38.1% | 0.5 |
| 2022 | 34.6% | 13.5% | 54.6% | 0.5 |
| 2023 | 59.7% | 14.7% | 34.9% | 0.4 |
| 2024 | 36.1% | 18.7% | 15.4% | 0.9 |

**Analysis:**

* LLY has consistently outperformed the S&P 500, with a significantly higher cumulative return.
* LLY has a high alpha, indicating that it has generated returns beyond what would be expected based solely on its beta (market exposure). 
* However, it's important to note that LLY's beta varies across years, which can be attributed to fluctuations in the company's growth and market sentiment.

**2. Recent Price Movement:**

* **Closing Price:** 806.14
* **Last Market Price:** 806.44
* **5-Day Moving Average:** 841.04
* **20-Day Moving Average:** 893.7
* **60-Day Moving Average:** 911.71

**Analysis:**

* LLY's price is currently below all moving averages, indicating a downward trend.
* The recent market price indicates a slight uptick, which may be a short-term rebound. 

**3. Technical Indicators:**

* **RSI:** 13.55
* **PPO:** -1.26
* **20-Day Relative Divergence Change:** -12.33

**Analysis:**

* **RSI:** Suggests LLY is in oversold territory, implying potential for a bounce back. 
* **PPO:** Negative value indicates bearish momentum. 
* **Relative Divergence:**  The negative change indicates a short-term downtrend in relative performance compared to the market.

**Expected Return:** 97.79% (Expected long-term outperformance over the S&P 500) 

**4. Recent Earnings and Outlook**

**Earnings Summary:**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2024-10-30 | 1.08 | $11.44 B$ |
| 2024-08-08 | 3.29 | $11.30 B$ |
| 2024-04-30 | 2.49 | $8.77 B$ |
| 2023-11-02 | -0.06 | $9.50 B$ |
| 2024-10-30 | -0.06 | $9.50 B$ |

**Analysis:**

* LLY's most recent earnings exceeded analyst expectations, driving a strong stock price rebound.
* The company has shown consistent revenue growth, demonstrating strong demand for its products. 
* However, analysts expect a slower growth rate in the near future.

**5. Financial Information**

**Revenue and Profitability:**

| Quarter     | Revenue | Profit Margin |
|------------|---------|---------------|
| 2024-09-30 | $11.44B | 81.02%       |
| 2024-06-30 | $11.30B | 80.80%       |
| 2024-03-31 | $8.77B  | 80.91%       |
| 2023-12-31 | $9.35B  | 80.88%       |
| 2023-09-30 | $9.50B  | 80.42%       |

**Capital and Profitability:**

| Quarter     | Equity | ROE  |
|------------|--------|------|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

**Analysis:**

* LLY boasts strong profitability with a high and consistent profit margin, indicating efficient operations.
* The company's ROE has been generally positive and high, demonstrating strong returns on shareholder equity. However, there was a dip in Q3 2023, which may be due to market factors or strategic investments.

**6. News and Recent Developments**

* **Recent Earnings Release:** LLY's most recent earnings release on October 30, 2024, exceeded analyst expectations for both EPS and revenue. 
* **Analyst Opinions:** The majority of analysts rate LLY as a "Buy" or "Strong Buy", citing its strong financials, promising pipeline, and potential for future growth. 
* **Recent Market Outlook:** The stock has been under pressure recently due to a broader market downturn and concerns over the company's growth prospects. However, many analysts believe that this presents a buying opportunity for long-term investors. 

**7. Overall Analysis**

LLY is a strong and profitable pharmaceutical company with a promising future. The stock has consistently outperformed the market over the long term and possesses strong fundamentals. Despite recent market headwinds and a slight dip in price, its strong earnings, high profitability, and positive analyst outlook suggest potential for future growth.  

**For long-term investors seeking exposure to the healthcare sector with a focus on innovation and strong financial performance, Eli Lilly and Co. (LLY) remains a compelling investment opportunity.** 
